All In Biotech

Drug Trial Radar · NCT01154816

Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias

Last checked: Nov 19, 2026Latest source record: May 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

118

Actual

Start

Feb 2011

Primary completion

Dec 31, 2015

Study completion Jun 30, 2019

Sponsor

Lead sponsor
Children's Oncology GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Jul 1, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 1 year, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial is studying the side effects of and how well alisertib works in treating young patients with relapsed or refractory solid tumors or leukemia. Alisertib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Hepatoblastoma
  • Previously Treated Childhood Rhabdomyosarcoma
  • Recurrent Childhood Acute Lymphoblastic Leukemia
  • Recurrent Childhood Acute Myeloid Leukemia
  • Recurrent Childhood Kidney Neoplasm
  • Recurrent Childhood Malignant Germ Cell Tumor
  • Recurrent Childhood Rhabdomyosarcoma
  • Recurrent Childhood Soft Tissue Sarcoma
  • Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
  • Recurrent Neuroblastoma
  • Recurrent Osteosarcoma

Interventions

  • AlisertibDrug

    Given orally

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • Pharmacological StudyOther

    Correlative studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Overall ResponseTime frame: From first dose of alisertib through 6 cycles of protocol therapy or until removal from protocol therapy whichever occurred first.

Locations

105 sites in 2 countries. Site status is shown where the registry gives one.

  • Children's Hospital of Alabama

    Birmingham, Alabama

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Southern California Permanente Medical Group

    Downey, California

  • Miller Children's and Women's Hospital Long Beach

    Long Beach, California

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Children's Hospital Central California

    Madera, California

  • Children's Hospital of Orange County

    Orange, California

  • Lucile Packard Children's Hospital Stanford University

    Palo Alto, California

  • Rady Children's Hospital - San Diego

    San Diego, California

  • UCSF Medical Center-Parnassus

    San Francisco, California

  • Connecticut Children's Medical Center

    Hartford, Connecticut

  • Yale University

    New Haven, Connecticut

  • Alfred I duPont Hospital for Children

    Wilmington, Delaware

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Lee Memorial Health System

    Fort Myers, Florida

  • Nemours Children's Clinic-Jacksonville

    Jacksonville, Florida

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida

  • Florida Hospital Orlando

    Orlando, Florida

  • Nemours Children's Clinic - Orlando

    Orlando, Florida

  • UF Cancer Center at Orlando Health

    Orlando, Florida

  • Nemours Children's Clinic - Pensacola

    Pensacola, Florida

  • All Children's Hospital

    St. Petersburg, Florida

  • Saint Joseph's Hospital/Children's Hospital-Tampa

    Tampa, Florida

  • Children's Healthcare of Atlanta - Egleston

    Atlanta, Georgia

  • University of Hawaii Cancer Center

    Honolulu, Hawaii

  • Lurie Children's Hospital-Chicago

    Chicago, Illinois

  • University of Illinois

    Chicago, Illinois

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois

  • Saint Jude Midwest Affiliate

    Peoria, Illinois

  • Southern Illinois University School of Medicine

    Springfield, Illinois

  • Indiana University/Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana

  • Riley Hospital for Children

    Indianapolis, Indiana

  • University of Iowa/Holden Comprehensive Cancer Center

    Iowa City, Iowa

  • University of Kentucky/Markey Cancer Center

    Lexington, Kentucky

  • Tulane University Health Sciences Center

    New Orleans, Louisiana

  • Sinai Hospital of Baltimore

    Baltimore, Maryland

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

Showing 40 of 105 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.